Hemorrhage Clinical Trial
Official title:
Comparison of 4 Tactical Tourniquets Used in War Medicine
Verified date | July 2021 |
Source | Direction Centrale du Service de Santé des Armées |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Bleeding remains the leading cause of death in combat, and the literature suggests that tourniquetable hemorrhage is the second leading cause of preventable death, behind non- tourniquetable hemorrhage. Currently, most Western armed forces recommend the use of the tactical tourniquet in combat for the management of tourniquetable hemorrhage. The SOFTT® tourniquet (Tactical Medical Solutions, Anderson) is the tactical tourniquet currently in use by the French armed forces. As the contract will soon come to an end, the question of its renewal arises. The purpose of this study is to compare 4 commercially available tactical tourniquets in healthy volunteers. The hypothesis of the research is that one of the 4 tourniquets compared is faster to set up than the others.
Status | Completed |
Enrollment | 46 |
Est. completion date | June 14, 2021 |
Est. primary completion date | June 14, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years; - Student of the Military Health School of Lyon Bron (Ecoles Militaires de Santé de Lyon Bron; EMSLB); - Periodic medical examination up to date with the mention "fitness for duty"; - Holder of the "Combat Rescue Level 1" training. Exclusion Criteria: - Vascular pathology; - Current progressive pathology of any kind; - History of thrombo-embolic disease; - Presence of cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking > 1 cigarette/day, BMI > 25); - Iliofemoral and axillary vascular abnormalities detected by systematic Doppler ultrasound; - Presence of symptoms suggestive of COVID-19; - Positive COVID-19 antigen test; - In contact with a person diagnosed positive for COVID-19 within 15 days prior to inclusion; - Pregnant or breastfeeding woman. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital d'Instruction des Armées Desgenettes | Lyon |
Lead Sponsor | Collaborator |
---|---|
Direction Centrale du Service de Santé des Armées |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time required to apply the tactical tourniquet. | The tourniquet application time, in seconds, measured with a stopwatch. The stopwatch will be started when the fitter takes the tourniquet, pre-positioned in a tourniquet pouch on his bullet vest.
The stopwatch will be stopped as soon as at least one of the following conditions is verified the fitter judges the fitting to be effective the fitter cannot tighten any more (technical limit) the tourniquet is too painful for the receiver. |
Each day during 4 consecutive days | |
Secondary | Occlusion of the downstream arterial flow following after tactical tourniquet application | The occlusion of the downstream arterial flow will be assessed by medical ultrasound after tactical tourniquet application | Each day during 4 consecutive days | |
Secondary | Ease of use of the tactical tourniquet | The ease of use of the tactical tourniquet will be measured via a 5-point scale: "very easy", "easy", "intermediate", "hard" and "very hard". | Each day during 4 consecutive days | |
Secondary | Rusticity of the tactical tourniquet | The rusticity of the tactical tourniquet will be assessed via a questionnaire: "sufficiently rustic" or "not sufficiently rustic" | Each day during 4 consecutive days | |
Secondary | Stability of the tactical tourniquet | The stability of the tactical tourniquet will be assessed via a questionnaire, on a 5-point scale: "unstable", "not very stable", "moderately stable", "stable" or "extremely stable". | Each day during 4 consecutive days | |
Secondary | Pain experienced by the receiver during application of the tactical tourniquet | Pain experienced by the receiver during application of the tactical tourniquet, measured by a scale ranging from 0 (no pain) to 10 (most unbearable pain). | Each day during 4 consecutive days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02815670 -
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
|
Phase 3 | |
Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Completed |
NCT02569606 -
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
|
||
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT01935427 -
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
|
N/A | |
Completed |
NCT01955720 -
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
|
Phase 1 | |
Recruiting |
NCT01709786 -
Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
|
N/A | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
Completed |
NCT01191554 -
Dose-ranging Study of Tranexamic Acid in Valve Surgery
|
N/A | |
Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
Completed |
NCT01085006 -
The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
|
Phase 1/Phase 2 | |
Completed |
NCT00700141 -
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
|
N/A | |
Completed |
NCT00375466 -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
|
N/A | |
Completed |
NCT00147420 -
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|
N/A | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
Completed |
NCT03273322 -
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 |